Core Viewpoint - The stock of Lideman has experienced a significant surge, achieving three consecutive daily limit-ups, with a total increase of 72.74% during this period, indicating strong market interest and potential investor confidence [2] Trading Performance - As of 14:05, the stock price reached 10.14 yuan, with a turnover rate of 29.67% and a trading volume of 1.61 billion shares, resulting in a transaction amount of 1.444 billion yuan [2] - The stock has been listed on the "Dragon and Tiger List" due to a cumulative price deviation of 30% over three trading days and a daily price increase of 15% [2] - Institutional investors have net sold 32.43 million yuan, while other trading desks collectively net bought 71.06 million yuan [2] Shareholder Structure - As of July 31, the number of shareholders decreased to 17,047, a decline of 622 from the previous period, indicating a continuous concentration of shares [2] Financial Performance - The company reported a total revenue of 79 million yuan for Q1, a year-on-year decrease of 16.61%, and a net profit of -1.25 million yuan, which is a 53.73% increase compared to the previous year [2] Recent Stock Movements - The stock's daily performance over the last few trading days shows fluctuations in price and turnover, with notable net inflows and outflows of capital [2]

Group 1 - The medical device sector continues to rise, with Lidman hitting a 20cm limit up [1] - Dabo Medical previously reached a limit up, indicating strong market interest [1] - Companies such as Zhijiang Biology, Yirui Biology, and Kangzhong Medical are also experiencing significant increases [1]

Market Overview - The Shanghai Composite Index fell by 0.94% this week, with six industries experiencing gains, led by the pharmaceutical and biotechnology sector, which rose by 2.95% [1] - The coal and non-ferrous metals industries saw the largest declines, with drops of 4.67% and 4.62% respectively [1] Fund Flow Analysis - A total of 211.86 billion yuan was net withdrawn from the two markets this week, with only the banking sector seeing a net inflow of 4.33 billion yuan [1] - The non-ferrous metals industry had the highest net outflow, totaling 25.99 billion yuan, followed by the computer industry with a net outflow of 20.45 billion yuan [1][2] Pharmaceutical and Biotechnology Sector - The pharmaceutical and biotechnology sector had a net outflow of 4.68 billion yuan this week, despite a price increase of 2.95% [3] - Out of 474 stocks in this sector, 323 stocks rose, with notable gainers including Nanjing New Pharmaceutical (up 78.01%), Lide Man (up 46.45%), and Chenxin Pharmaceutical (up 40.88%) [3] - The sector also saw 36 stocks with net outflows exceeding 100 million yuan, with WuXi AppTec leading at 1.98 billion yuan [3][4] Top Gainers and Losers in Pharmaceutical Sector - The top gainers in the pharmaceutical sector included: - Zhongsheng Pharmaceutical: up 29.52% with a net inflow of 1.01 billion yuan - Anke Bio: up 25.93% with a net inflow of 0.36 billion yuan - Lianhuan Pharmaceutical: up 15.99% with a net inflow of 0.34 billion yuan [3] - The top losers included: - WuXi AppTec: down 4.64% with a net outflow of 1.98 billion yuan - Borui Pharmaceutical: down 0.14% with a net outflow of 0.71 billion yuan - Kanglong Chemical: up 0.33% with a net outflow of 0.51 billion yuan [4]

Group 1 - The company's stock price experienced a significant fluctuation, with a cumulative increase of 45.06% over two consecutive trading days (July 31, 2025, and August 1, 2025), which exceeds the 30% threshold for abnormal trading as per Shenzhen Stock Exchange regulations [1] - The company conducted a comprehensive self-examination and verified the situation with its controlling shareholders, actual controllers, and all board members regarding the abnormal stock price movement [1] - The company is in the preliminary planning stage of a major asset restructuring, intending to acquire up to 70% of Beijing Xiansheng Xiangrui Biological Products Co., Ltd. through cash [1] Group 2 - The transaction is classified as a major asset restructuring under the relevant regulations, and the company is still in the early stages of planning, requiring further validation and negotiation of the transaction terms [1] - There are risks associated with the inability to complete necessary internal and external decision-making and approval processes for the transaction [1] - The company confirmed that there are no undisclosed significant matters related to the company or any other major matters in the planning stage [1]

Market Overview - As of August 1, the Shanghai Composite Index closed at 3559.95 points, with a decline of 0.37%. The Shenzhen Component Index closed at 10991.32 points, down 0.17%, and the ChiNext Index closed at 2322.63 points, decreasing by 0.24% [1]. Trading Volume Analysis - A total of 1503 stocks saw an increase in average transaction volume, with 31 stocks experiencing a rise of over 50%. Conversely, 3051 stocks reported a decrease in average transaction volume [1]. - Notable stocks with significant increases in average transaction volume include Kecuan Technology, Shenghui Integration, and Zhengzhong Design [1]. Active Stocks by Transaction Volume - The stocks with the highest increase in average transaction volume on August 1 include: - Kecuan Technology: 9.99% increase, average transaction volume of 1014 shares, up 193.10% [3]. - Shenghui Integration: 10.00% increase, average transaction volume of 672 shares, up 191.70% [3]. - Zhengzhong Design: 10.00% increase, average transaction volume of 2134 shares, up 168.74% [3]. Active Stocks by Transaction Count - The stocks with the highest increase in transaction count on August 1 include: - Anzheng Fashion: -1.69% change, with 68,433 transactions, up 1618.56% [2]. - Yingweike: 2.04% change, with 218,079 transactions, up 1082.38% [2]. - Zhongjiabo Chuang: -3.90% change, with 48,487 transactions, up 656.19% [2]. Stocks with Significant Increases in Both Volume and Count - Kecuan Technology stands out with a 9.99% increase, an average transaction volume of 1014 shares (up 193.10%), and a transaction count of 16,921 (up 126.52%) [4]. - Other notable stocks include: - Jiejia Weichuang: 20.00% increase, average transaction volume of 838 shares (up 130.45%), and 57,709 transactions (up 121.19%) [4]. - Riyi Electronics: 10.01% increase, average transaction volume of 846 shares (up 113.00%), and 25,112 transactions (up 161.72%) [4].

新京报贝壳财经讯8月1日，利德曼（300289）公告，公司股票交易价格连续两个交易日(2025年7月31 日、2025年8月1日)收盘价格涨幅偏离值累计达到45.06%。经自查及核实，公司前期披露的信息不存在 需要更正、补充之处，未发现近期公共传媒报道了可能或已经对公司股票交易价格产生较大影响的未公 开重大信息。公司目前经营情况正常，近期公司生产经营情况及内外部经营环境未发生变化。此外，公 司正在筹划重大资产重组事项，拟以现金方式收购北京先声祥瑞生物制品股份有限公司不超过70%股 份。该交易尚处于初步筹划阶段，存在不确定性及风险。 ...

Group 1 - The 2025 version of the chikungunya treatment plan has been released, leading to a rise in companies like Lide Man and Rejing Bio, boosting the medical device sector [1] - The medical device ETF (562600) closed up by 0.67% [1] - The 11th batch of centralized procurement has been initiated, with the National Medical Insurance Administration announcing measures to alleviate low-price competition in the industry [1] Group 2 - The National Medical Products Administration released measures in early July to support the innovation and development of high-end medical devices [1] - There is a positive outlook for innovative drugs and devices due to clear policy support in regulation and payment, which is expected to accelerate the development of domestic high-end devices [1] - The medical device ETF (562500) has a brain-computer interface component of 22.72%, leading the market and is expected to benefit from the growing interest in brain-computer interfaces [1]

利德曼公告，公司股票交易价格连续两个交易日（2025年7月31日、2025年8月1日）收盘价格涨幅偏离 值累计达到45.06%。经自查及核实，公司前期披露的信息不存在需要更正、补充之处，未发现近期公 共传媒报道了可能或已经对公司股票交易价格产生较大影响的未公开重大信息。公司目前经营情况正 常，近期公司生产经营情况及内外部经营环境未发生变化。此外，公司正在筹划重大资产重组事项，拟 以现金方式收购北京先声祥瑞生物制品股份有限公司不超过70%股份。该交易尚处于初步筹划阶段，存 在不确定性及风险。 ...

证券代码：300289 证券简称：利德曼 公告编号：2025-030 北京利德曼生化股份有限公司 关于公司股票交易异常波动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、股票交易异常波动的具体情况 北京利德曼生化股份有限公司（以下简称"公司"）股票交易价格连 续两个交易日（2025 年 7 月 31 日、2025 年 8 月 1 日）收盘价格涨幅偏 离值累计达到 45.06%（超过 30%），根据深圳证券交易所相关规定，属 于股票交易异常波动的情形。 二、公司关注并核实相关情况 6、公司不存在违反信息公平披露的情形。 三、不存在应披露而未披露信息的说明 针对公司股票异常波动的情况，公司董事会进行了全面自查，并对 控股股东、实际控制人及公司全体董事、监事、高级管理人员就有关事 项进行了核实，现将具体情况说明如下： 1、公司前期披露的信息不存在需要更正、补充之处； 2、公司未发现近期公共传媒报道了可能或已经对公司股票交易价格 产生较大影响的未公开重大信息； 3、公司目前经营情况正常，近期公司生产经营情况及内外部经营环 境未发生变化； 4、公司正在筹划重 ...

Strong Stocks - As of August 1, the Shanghai Composite Index fell by 0.37% to 3559.95 points, the Shenzhen Component Index decreased by 0.17% to 10991.32 points, and the ChiNext Index dropped by 0.24% to 2322.63 points [1] - A total of 51 stocks in the A-share market hit the daily limit up, with the top three strong stocks being Tianfu Wenlv (000558), Yatai Pharmaceutical (002370), and Lideman (300289) [1] - The detailed data for the top 10 strong stocks includes metrics such as trading volume, turnover rate, and industry classification [1] Strong Concept Sectors - The top three concept sectors with the highest increase in A-shares are Animal Vaccines, DRG/DIP, and BC Batteries, with respective increases of 2.22%, 1.87%, and 1.71% [2] - The detailed data for the top 10 concept sectors includes metrics such as the proportion of limit-up stocks and the proportion of rising and falling stocks [2]